Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lisavanbulin - Basilea Pharmaceutica

Next Previous
X
Search
Drug Profile

Lisavanbulin - Basilea Pharmaceutica

Alternative Names: B553; BAL 101553

Latest Information Update: 24 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Basilea Pharmaceutica
  • Developer Basilea Pharmaceutica; The Adult Brain Tumor Consortium
  • Class Antineoplastics; Imidazoles; Oxadiazoles; Small molecules
  • Mechanism of Action Apoptosis stimulants; Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Brain cancer; Breast cancer; Glioblastoma; Solid tumours

Most Recent Events

  • 20 Jun 2024 Basilea Pharmaceutica enteres into an asset purchase agreement with the Glioblastoma Foundation for lisavanbulin
  • 20 Jun 2024 Discontinued - Phase-I for Glioblastoma (First-line therapy) in USA (PO)
  • 20 Jun 2024 Discontinued - Phase-I/II for Glioblastoma (Late-stage disease, Recurrent) in United Kingdom (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top